OverviewSuggest Edit

Oncimmune is a leading early cancer detection company. It has pioneered the development of autoantibody assay technologies that have the potential to allow cancer detection up to four years earlier than other methods and be applied to a wide range of solid tumour types. In 2009, Oncimmune launched its proprietary platform technology for early cancer detection, called EarlyCDT®. The first test, EarlyCDT®-Lung, was commercialised in 2009 and test marketed until 2012, at which time it launched nationally across the US and since over 125,000 commercial tests have been sold. It is now available through physicians in the US and also privately in the UK and other regions. EarlyCDT®-Lung is a simple blood test which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. Oncimmune Ltd is headquartered in Nottingham, UK and testing is conducted in our CLIA-approved laboratory, based in Kansas City, USA.
TypePrivate
Founded2006
HQLenton Lane Industrial Estate, GB
Websiteoncimmune.com

Locations

Oncimmune is headquartered in
Lenton Lane Industrial Estate, United Kingdom

Location Map

Latest Updates

Employees (est.) (Sept 2020)57(+2%)
Revenue (FY, 2018)£104 K(+30%)
Cybersecurity ratingAMore

Key People/Management at Oncimmune

Adam M Hill

Adam M Hill

Chief Executive Officer, Director
Meinhard Schmidt

Meinhard Schmidt

Chairman
Matthew Hall

Matthew Hall

Chief Financial Officer
Tim Bunting

Tim Bunting

Non Executive Director
Andrea Murray

Andrea Murray

Chief Operational Scientist
Julian Hirst

Julian Hirst

Non-Executive Director
Show more

Oncimmune Office Locations

Oncimmune has offices in Lenton Lane Industrial Estate, Nottingham, De Soto, Leawood and in 1 other location
Lenton Lane Industrial Estate, GB (HQ)
1 Thane Rd
Nottingham, GB
Hucknall Rd
Dortmund, DE
Otto-Hahn-Straße 15
De Soto, US
8960 Commerce Dr
Leawood, US
4000 W 114th St #170
Show all (5)

Oncimmune Financials and Metrics

Summary Metrics

Founding Date

2006

Oncimmune total Funding

$15 m

Oncimmune latest funding size

$15 m

Time since last funding

4 years ago

Oncimmune investors

Oncimmune's latest funding round in January 2017 was reported to be $15 m. In total, Oncimmune has raised $15 m
Show all financial metrics

Oncimmune Revenue

Oncimmune's revenue was reported to be £104 k in FY, 2018
GBP

Revenue (FY, 2018)

104.0k

Gross profit (FY, 2018)

(154.0k)

Gross profit margin (FY, 2018), %

(148.1%)

Net income (FY, 2018)

(5.0m)

EBITDA (FY, 2018)

3.3m

EBIT (FY, 2018)

3.2m

Cash (31-May-2018)

8.5m
GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

1.4k15.4k55.0k149.4k1.5m1.1m1.3m303.0k80.0k104.0k

Revenue growth, %

(31%)27%(77%)

Cost of goods sold

136.3k140.5k2.9k248.0k258.0k

Gross profit

1.4m916.4k1.3m(168.0k)(154.0k)
GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

11.5k1.0m4.0m3.3m3.0m3.7m5.3m2.7m2.1m1.1m1.6m1.3m10.1m4.9m8.5m

Accounts Receivable

1.6k334.1k118.8k265.4k28.0k16.0k22.0k

Inventories

116.1k91.0k83.0k

Current Assets

19.8k1.0m4.2m3.4m3.2m3.8m6.4m2.8m2.3m1.9m2.4m1.9m10.5m5.1m8.8m
GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(198.9k)(546.9k)(1.5m)(2.6m)(3.9m)(6.6m)(6.1m)(4.3m)(4.4m)(3.0m)(1.4m)(2.0m)(1.8m)(4.0m)(5.0m)

Cash From Operating Activities

(3.4m)(5.3m)(4.7m)(4.5m)(4.1m)(3.2m)(2.3m)(1.4m)

Cash From Financing Activities

3.6m5.5m5.9m1.6m3.5m2.0m1.8m1.2m

Net Change in Cash

(348.2k)439.7k1.6m(2.6m)(534.9k)(1.1m)557.5k(310.3k)
GBPFY, 2004

Financial Leverage

-0.1 x
Show all financial metrics

Oncimmune Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Oncimmune Online and Social Media Presence

Embed Graph

Oncimmune Frequently Asked Questions

  • When was Oncimmune founded?

    Oncimmune was founded in 2006.

  • Who are Oncimmune key executives?

    Oncimmune's key executives are Adam M Hill, Meinhard Schmidt and Matthew Hall.

  • How many employees does Oncimmune have?

    Oncimmune has 57 employees.

  • What is Oncimmune revenue?

    Latest Oncimmune annual revenue is £104 k.

  • What is Oncimmune revenue per employee?

    Latest Oncimmune revenue per employee is £1.8 k.

  • Who are Oncimmune competitors?

    Competitors of Oncimmune include PatientsLikeMe, Independa and Ingenious Med.

  • Where is Oncimmune headquarters?

    Oncimmune headquarters is located at 1 Thane Rd, Lenton Lane Industrial Estate.

  • Where are Oncimmune offices?

    Oncimmune has offices in Lenton Lane Industrial Estate, Nottingham, De Soto, Leawood and in 1 other location.

  • How many offices does Oncimmune have?

    Oncimmune has 5 offices.